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ABSTRACT
Objective: Cardiac guidelines recommend that the
decision to perform coronary angiography (CA) in
patients with Non-ST-Elevation Acute Coronary
Syndrome (NST-ACS) is based on multiple factors.
It is, however, unknown how cardiologists weigh these
factors in their decision-making. The aim was to
investigate the importance of different clinical
characteristics, including information derived from risk
scores, in the decision-making of Dutch cardiologists
regarding performing CA in patients with suspected
NST-ACS.
Design: A web-based survey containing clinical
vignettes.
Setting and participants: Registered Dutch
cardiologists were approached to complete the survey,
in which they were asked to indicate whether they
would perform CA for 8 vignettes describing 7 clinical
factors: age, renal function, known coronary artery
disease, persistent chest pain, presence of risk factors,
ECG findings and troponin levels. Cardiologists were
divided into two groups: group 1 received vignettes
‘without’ a risk score present, while group 2 completed
vignettes ‘with’ a risk score present.
Results: 129 (of 946) cardiologists responded. In both
groups, elevated troponin levels and typical ischaemic
changes (p<0.001) made cardiologists decide more
often to perform CA. Severe renal dysfunction
(p<0.001) made cardiologists more hesitant to decide
on CA. Age and risk score could not be assessed
independently, as these factors were strongly
associated. Inspecting the factors together showed, for
example, that cardiologists were more hesitant to
perform CA in elderly patients with high-risk scores
than in younger patients with intermediate risk scores.
Conclusions: When deciding to perform in-hospital
CA (≤72 hours after patient admission) in patients with
suspected NST-ACS, cardiologists tend to rely mostly
on troponin levels, ECG changes and renal function.
Future research should focus on why CA is less often
recommended in patients with severe renal
dysfunction, and in elderly patients with high-risk
scores. In addition, the impact of age and risk score
on decision-making should be further investigated.
BACKGROUND
The management of patients with Non-ST-
Elevation Acute Coronary Syndrome (NST-
ACS), including Non-ST-Elevation Myocardial
Infarction (NSTEMI) and Unstable Angina
(UA), is challenging. Physicians deal with the
difﬁcult task of identifying patients at high
risk for adverse cardiac events who would
beneﬁt most from invasive therapies, such as
percutaneous coronary intervention (PCI) or
coronary artery bypass grafting (CABG),
while preventing unnecessary invasive proce-
dures in low risk patients in whom conserva-
tive therapies are appropriate.1 Recent
guidelines from the European Society of
Cardiology (ESC) for the management of
patients with NST-ACS recommend that car-
diologists base their decision regarding
Strengths and limitations of this study
▪ This study provides insight into how cardiolo-
gists weigh clinical information in deciding on
performing coronary angiography (CA) or not in
patients with suspected Non-ST-Elevation Acute
Coronary Syndrome.
▪ The decision had to be made on the basis of
seven attributes, while in clinical practice cardiol-
ogists may take into account other aspects in
their decision-making as well. However, clinical
vignette studies have been shown to be the most
practical, cost-effective and at the same time
thorough and valid approach to measure the
process of decision-making.
▪ The response rate on the web-based survey, con-
taining clinical vignettes, was low. Nevertheless,
despite the wider CIs of ORs, several significant
associations were found. Therefore, this study
provides further insight into decision processes
of cardiologists offering a valuable contribution
to the modest number of studies conducted in
the field of decision-making in cardiology so far.
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coronary angiography (CA) and subsequent treatments
on multiple factors, including a patient’s cardiac history,
risk factors for coronary artery disease (CAD), results
from physical examination, laboratory results and ECG
ﬁndings.1 2 Furthermore, it is recommended that physi-
cians use objective risk scoring instruments, such as
Global Registry of Acute Coronary Events (GRACE) or
Thrombolysis in Myocardial Infarction (TIMI), in
guiding risk stratiﬁcation and management.1–5 In
patients at intermediate or high risk for cardiac adverse
events, CA within 72 or 24 hours, respectively, after hos-
pital admission is indicated, except in case of severe
contra-indications such as active bleeding or the pres-
ence of major comorbidities.1 2 Timing of CA and, if
indicated, subsequent revascularisation should thus be
based on the patient’s risk status. Previous studies,
however, demonstrated that patients at high risk for
cardiac adverse events were often less likely to undergo
CA than low-risk patients.6–11 A possible explanation for
such a treatment risk paradox may be the cardiologists’
reluctance to perform invasive procedures in patients
with high-risk features, such as high age and acute heart
failure, because of a perceived increased risk of
procedure-related adverse events (ie, contrast-induced
kidney injury, bleeding, stroke or even death).1 2 12–14
Further, a recent study in 13 Dutch hospitals showed that
compliance to cardiac risk scores in clinical practice is
relatively low and that risk score use varies largely
between hospitals.15 However, data were collected retro-
spectively, and it is therefore unknown whether the infor-
mation derived by using a cardiac risk score actually
inﬂuenced the cardiologists’ treatment decisions in this
recent study. The exact importance of various clinical
characteristics and risk score outcomes on the decision to
perform prompt invasive management remains unclear.
Therefore, the aim of this study was to investigate the rela-
tive importance of different clinical characteristics, includ-
ing information derived from risk scores, in the
decision-making of Dutch cardiologists regarding per-
forming CA in patients with suspected NST-ACS.
METHODS
This study used a binary choice experiment to study the
relative importance of different clinical characteristics,
including information derived from risk scores, in the
decision-making of Dutch cardiologists.
Survey
A web-based survey containing the binary choice experi-
ments was sent to all 946 cardiologists who were regis-
tered in the Dutch directory of physicians in the year
2014. The survey started with an informed consent pro-
cedure, explaining the purpose of the study and the
option to decline participation. To describe respondents’
characteristics, each cardiologist was subsequently asked
to register his/her age, gender and working experience
in years. In addition, they were asked whether they are
employed in a hospital with a teaching status (yes/no),
with revascularisation options (no, PCI or PCI/CABG)
and whether they used a cardiac risk score at the coron-
ary care unit. Responding cardiologists who were retired
or no longer active in practice were excluded from ana-
lysis. For a detailed description of the study, we refer to
the previously published study protocol.16
Factors: selection and choice of levels
The binary choice experiments consisted of vignettes of
clinical cases. Based on literature review and expert
opinion, seven essential factors representing clinical
characteristics were identiﬁed on which cardiologists were
likely to base their decision to perform CA, that is,: age,
renal function, known CAD, persistent chest pain, pres-
ence of risk factors for CAD (ie, diabetes mellitus, hyper-
tension, hypercholesterolaemia, smoking and a positive
family history), electrocardiogram ﬁndings and high sen-
sitive troponin levels. Respondents were instructed to
interpret the factor troponin levels (positive/negative)
according to their own hospital standards. The factors
have different levels, which are depicted in table 1.
In addition to the aforementioned factors, the
patient’s cardiac risk of adverse events was estimated for
every clinical vignette by using the GRACE 2.0 risk score
leading to the following risk categories: low, intermedi-
ate and high.17 This was accomplished by entering the
values present in the vignette, and entering similar
values of ‘severity’ for the remaining parameters (ie,
diuretic use, heart rate, systolic blood pressure, Killip
class and cardiac arrest at admission) in every vignette.
The sample of cardiologists was divided into two
groups before the start of the survey.16 One group com-
pleted the vignettes ‘without’ a cardiac risk score being
present (group 1), while the other group completed the
vignettes ‘with’ a cardiac risk score present (group 2).
Cardiologists in the latter group were instructed that the
reported risk categories were generated by the risk score
that they apply in their own practice, as it was not speci-
ﬁed that it was the result of the GRACE 2.0 risk score.
Experimental design
The vignettes were systematically varied on the afore-
mentioned clinical factors (factorial design): age, renal
function, known CAD, persistent chest pain, presence of
risk factors, ECG ﬁndings and troponin levels. When
combining all factors and factor levels, 23×34=648 unique
clinical vignettes were created (full factorial design).
From these vignettes, a G-optimal design of 64 vignettes
was selected that allowed for estimation of all main
effects, employing the computer algorithm implemented
by Wheeler.18 The 64 scenarios were randomly allocated
to eight blocks containing eight vignettes each.
Cardiologists were randomly assigned to a block of eight
vignettes. For each of the eight vignettes included in the
survey, cardiologists were asked to decide whether they
would perform CA within 72 hours after patient admis-
sion or would not perform CA (yes or no).
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Data analysis
The strength of associations between independent vari-
ables (ie, factors) and decisions of cardiologists in the
survey (yes/no CA) were estimated using a generalised
linear mixed model (GLMM) for binary response data,
and expressed as ORs (ORs). Random effects for cardi-
ologists were added to this model to account for the clus-
tering of data within cardiologists. Separate GLMM
models were created for group 1 (vignettes without a
risk score) and group 2 (vignettes with a risk score). The
various factors, the variable risk score (group 2 only)
and the block factor, were simultaneously entered as
ﬁxed effects to the model. Since the number of blocks is
relatively small, blocks were not introduced as random
effects in the model as the associated component of vari-
ance cannot be estimated with acceptable accuracy. For
that reason, block effects were introduced as ﬁxed
effects in the analysis. As a check for partial confound-
ing/near multicollinearity, in table 4, ORs from multi-
variable analyses (and their SEs and CIs) were compared
with ORs from univariable analyses (at all times includ-
ing ﬁxed block effects and random cardiologists effects
in the model). Signiﬁcance tests were based on the like-
lihood ratio test. In addition, for independent factors
with three factor levels, pairwise comparisons, that is,
level 1 vs 2, level 1 vs 3, and level 2 vs 3, were made using
the Wald test. Effect sizes were expressed in terms of
ORs and their associated 95% CI. p Values equal to or
below 0.05 were considered signiﬁcant. The impact of
the presence of the risk score on a cardiologist’s decision
was studied by comparing ORs and p values of the ana-
lyses of group 1 with group 2. The analyses with the
GLMM were conducted in R for windows (V.3.1.3) (R
Core Team. R: A language and environment for statis-
tical computing. R Foundation for Statistical Computing,
2013. http://www.R-project.org/ (accessed Jan 2014)).
The multivariable GLMMs of the two groups were
used to determine the relative importance of each factor
in deciding on CA. Relative importance refers to the
contribution of a speciﬁc factor to the total deviance
(−2×log likelihood) of the multivariable model. It was
calculated by taking the difference between the
deviances of the multivariable model with all factors
present and a model with one of the factors of interest
removed. The resulting differences were converted to
percentages for each factor by dividing the difference by
the sum of contributions of all independent factors,
multiplying by 100.19 Interpretation of relative import-
ance measures is similar to the percentage of variance
accounted for in ordinary regression.
In the study protocol, we considered the degree of
perceived certainty of decisions as a possible covariate in
the GLMM.16 Effectively, this implies that results are
‘corrected’ for uncertainty. However, since uncertainty is
an integral part of the decision process, analyses that
‘corrected’ for uncertainty led to results that could not
be properly interpreted and the variable was not
included in the analyses.
RESULTS
Study population
A total of 946 Dutch cardiologists, 470 in group 1 and
476 in group 2, were approached by email to complete
the survey. A total of seven reminders were sent between
June and October 2014. Eventually, 14% (66/470) and
13% (63/476) of the cardiologists responded. In each
group, the answers of nine participants were not eligible
for analysis, due to missing informed consent, incom-
plete data or because cardiologists were not active in
practice anymore (ﬁgure 1). The ﬁnal sample consisted
of 57 cardiologists in group 1 and 54 cardiologists in
group 2. The majority of cardiologists who completed
the survey were male, had more than 10 years of clinical
experience, and were employed in a hospital with both
PCI and CABG options. There were no signiﬁcant
Table 1 Final selection of factors and their levels
Clinical setting: patient with suspected NST-ACS is admitted for observation in the hospital.
Decision: ‘would you perform coronary angiography within 72 hours in this patient?’
Factors Factor levels
Age <70 years
65 years in clinical vignette
70–80 years
75 years in clinical vignette
>80 years
85 years in clinical vignette
Renal function No renal dysfunction Mild to moderate renal
dysfunction
Severe renal dysfunction
Known coronary artery disease No Yes
Persistent chest pain No Yes
Risk factors* No risk factors One risk factor >One risk factor
ECG Normal Atypical changes Typical ischaemic changes
Troponin† Normal at repeated
measures
Significant rise and/or ‘rise and
fall’
*Diabetes mellitus, hypertension, hypercholesterolaemia, smoking and a positive family history.
†According to cardiologists’ own hospital standards.
NST-ACS,
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differences in characteristics of the cardiologists between
group 1 and group 2 (table 2). Detailed information
regarding responses of cardiologists on the clinical vign-
ettes is provided as supplementary material (see online
supplementary appendix A).
Relative importance of clinical factors
Group 1: vignettes without risk score present
For group 1, the following factors affected cardiologists’
decisions to perform CA within 72 hours the strongest
(in decreasing order): troponin levels (48.9%), ECG
changes (17.9%), renal function (11.8%), age (9.5%),
persistent chest pain (6.4%), previous CAD (2.9%) and
presence of risk factors (0.5%; table 3). When changing
from one level of a factor to another, the probability for
deciding to perform CA may be relatively strongly
affected, that is, for troponin levels or modestly affected,
that is, for presence of risk factors. This is what is
reﬂected in the percentage for relative importance of a
factor and in the estimated ORs.
Of the two factors affecting cardiologists’ decisions the
strongest, patients with a signiﬁcant rise and/or ‘rise
and fall’ of troponin levels, or with typical ischaemic
changes on the ECG, were more likely to receive CA
compared to patients with normal troponin levels or
with no changes or atypical changes on the ECG. Severe
renal dysfunction compared to no renal dysfunction or
mild to moderate renal dysfunction, and older age
Figure 1 Flow chart of respondent selection and survey response.
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(>80 years) compared to younger patients (<70 and 70–
80 years) made cardiologists decide less often to
perform CA. Presence of persistent symptoms of chest
pain or a history of CAD hardly seemed to affect cardiol-
ogists’ decisions. The presence of risk factors was not sig-
niﬁcantly (p=0.43) associated with the decision whether
or not to perform CA. The strengths of the multivariable
associations are presented in terms of ORs and asso-
ciated 95% CIs. Also in parentheses, the ORs and CIs of
the univariable analyses are presented for comparison
(table 4).
Group 2: vignettes with risk score present
For group 2, the following factors impacted cardiolo-
gists’ decisions to perform CA within 72 hours the stron-
gest (in decreasing order): troponin levels (49.6%),
renal function (14.9%), risk score (14.3%), ECG
changes (9.8%), persistent chest pain (6.7%), presence
of risk factors (0.7%), age (0.6%) and previous CAD
(0.00%; table 3).
Cardiologists decided more often to perform CA in
patients with a signiﬁcant rise and/or ‘rise and fall’ of
troponin levels than in patients with normal troponin
Table 2 Demographics of participating cardiologists
GROUP 1* (n=57) GROUP 2† (n=54) p Value‡
Gender 0.803
Male 48 (84.2%) 44 (81.5%)
Age≈ 50.0 (42.0–59.0) 49.5 (41.0–55.0) 0.125
<50 years 26 (45.6%) 27 (50.0%)
≥50 years 31 (54.4%) 27 (50.0%)
Working years≈ 12.0 (7.0–24.0) 11.0 (5.0–21.0) 0.172
<5 7 (12.3%) 11 (20.4%)
5–10 18 (31.6%) 16 (29.6%)
>10 32 (56.1%) 27 (50.0%)
Revascularisation options 0.805
No 18 (31.6%) 15 (27.8%)
Yes, PCI 13 (22.8%) 11 (20.4%)
Yes, PCI and CABG 26 (45.6%) 28 (51.9%)
Teaching hospital 0.424
Yes 35 (61.4%) 38 (70.4%)
Use of risk score at CCU§ 0.177
Yes 41 (71.9%) 45 (83.3%)
≈Median and accompanied 25th and 75th centile. All other data are presented in n (%).
*Group 1 refers to the group of responding cardiologists receiving the set of vignettes without a risk score present.
†Group 2 refers to the group of responding cardiologists receiving the set of vignettes with a risk score present.
‡Goodness of fit test for continuous variables with the Mann-Whitney U test, and for categorical variables with Pearson’s χ2 test or Fisher’s
Exact Test.
§GRACE, TIMI, FRISC and HEART risk score.
CABG, coronary artery bypass grafting; CCU, coronary care unit; FRISC, fast revascularisation in instability in coronary disease; GRACE,
Global Registry of Acute Coronary Events; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction.
Table 3 Importance of each factor in deciding whether or not to perform coronary angiography
Group 1 Group 2
Order of
importance Factor
Explained
deviance%* p Value†
Order of
importance Factor
Explained
deviance%* p Value†
1. Troponin 48.9% ≤0.001 1. Troponin 49.6% ≤0.001
2. ECG 17.9% ≤0.001 2. Renal function 14.9% ≤0.001
3. Renal function 11.8% ≤0.001 3. Risk score outcome 14.3%∞ 0.02
4. Age 9.5% ≤0.001 4. ECG 9.8% ≤0.001
5. Persistent chest pain 6.4% ≤0.001 5. Persistent chest pain 6.7% ≤0.001
6. Previous CAD 2.9% ≤0.001 6. Risk factors 0.7% 0.45
7. Risk factors 0.5% 0.43 7. Age 0.6%∞ 0.50
8. Risk score outcome NA NA 8. Previous CAD 0.0% 0.75
(Blocks)‡ (2.1%) – (Blocks)‡ (3.4%) –
Total 100% Total 100%
*Loglikelihood from a single attribute divided by the sum of partial loglikelihoods of all factors.
†p Value based on the loglikelihood test. ∞Factor risk score outcome is partially confounded by factor age, and therefore its impact cannot be
interpreted.
‡Explained deviance due to the allocation of cardiologists to blocks in the experimental design.
CAD, coronary artery disease; NA, not applicable.
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Table 4 Univariable and multivariable associations between a positive decision to order a CA and factors using Generalised Linear Mixed Models (GLMM)
Factor
GROUP 1 (n=57 cardiologists) GROUP 2 (n=54 cardiologists)
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Raw %
CA=yes‡ OR 95% CI LL-UL OR 95% CI LL–UL p Value*
Raw %
CA=yes‡ OR 95% CI LL–UL OR 95% CI LL–UL p Value*
Troponin levels
Elevated 80.6 13.7 8.25 to 22.69 66.90 26.29 to 170.25 ≤0.001 84.9 11.57 7.14 to 18.76 55.80 22.50 to 138.36 ≤0.001
Normal 26.9 1.0 1.0 33.9 1.0 1.0
ECG changes† ≤0.001 ≤0.001
Aspecific 43.0 1.04 0.66 to 1.65 1.13 0.54 to 2.39 0.74 49.3 1.13 0.71 to 1.82 2.00 0.88 to 4.56 0.10
Typical ischaemic 74.7 4.17 2.51 to 6.92 15.39 6.37 to 37.17 ≤0.001 77.7 4.05 2.41 to 6.79 16.40 4.80 to 56.05 ≤0.001
Normal 42.8 1.0 1.0 46.4 1.0 1.0
Age† ≤0.001 0.50
70–80 years 65.0 1.81 1.13 to 2.89 1.21 0.58 to 2.49 0.61 72.8 2.58 1.56 to 4.26 1.08 0.28 to 4.18 0.91
>80 years 42.0 0.72 0.45 to 1.14 0.14 0.05 to 0.34 ≤0.001 49.7 0.97 0.60 to 1.55 0.58 0.10 to 3.48 0.55
<70 years 51.7 1.0 1.0 51.4 1.0 1.0
Presence of risk factors† 0.43 0.45
1 risk factor 51.0 1.01 0.64 to 1.61 0.82 0.35 to 1.91 0.65 59.3 1.07 0.66 to 1.74 0.69 0.30 to 1.59 0.38
>1 risk factor 58.2 1.40 0.88 to 2.22 1.32 0.61 to 2.85 0.48 59.0 1.08 0.68 to 1.72 1.09 0.50 to 2.39 0.83
No risk factors 49.7 1.0 1.0 56.0 1.0 1.0
Renal dysfunction† ≤0.001 ≤0.001
Mild to moderate 54.1 0.62 0.38 to 0.99 0.52 0.23 to 1.18 0.12 64.3 1.36 0.84 to 2.21 2.17 0.84 to 5.60 0.11
Severe 39.4 0.33 0.21 to 0.54 0.09 0.04 to 0.21 ≤0.001 51.4 0.76 0.47 to 1.21 0.25 0.10 to 0.63 ≤0.001
No 66.0 1.0 1.0 58.7 1.0 1.0
Previous CAD
Yes 61.4 2.08 1.42 to 3.04 2.80 1.45 to 5.42 ≤0.01 57.3 0.93 0.63 to 1.37 0.94 0.50 to 1.78 0.75
No 44.1 1.0 1.0 59.0 1.0 1.0
Persistent chest pain
Yes 63.2 2.29 1.57 to 3.36 4.90 2.36 to 10.16 0.000 68.4 2.36 1.56 to 3.51 3.79 1.92 to 7.51 0.000
No 43.6 1.0 1.0 48.2 1.0 1.0
Risk score outcome† NA 0.02
Intermediate NA NA NA NA NA 63.7 4.41 2.60 to 7.49 4.40 0.84 to 22.93 0.08
High NA. NA NA NA NA 71.8 6.32 3.21 to 12.42 1.27 0.09 to 18.20 0.86
Low NA NA NA NA NA 32.7 1.0 1.0
Associations comparing level 2 vs 3 for the different factors were.
▪ ECG changes: typical ischaemic versus aspecific (GROUP 1: p 0.000, OR 13.57, CI 95% 5.65 to 32.60)/(GROUP 2: p 0.000, OR 8.20, CI 95% 2.87 to 23.46).
▪ Age: >80 years versus 70–80 years (GROUP 1: p 0.000, OR 0.11, CI 95% 0.05 to 0.27)/(GROUP 2: p 0.25, OR 0.53, CI 95% 0.18 to 1.55).
▪ Presence of risk factors: >1 risk factor versus 1 risk factor (GROUP 1: p 0.21, OR 1.61, CI 95% 0.77 to 3.36)/(GROUP 2: p 0.22, OR 1.56, CI 95% 0.76 to 3.32).
▪ Renal dysfunction: severe versus mild to moderate (GROUP 1: p 0.000, OR 0.17, CI 95% 0.07 to 0.39)/(GROUP 2: p 0.000, OR 0.12, CI 95% 0.05 to 0.26).
▪ Risk score outcome: high versus intermediate (GROUP 2: p 0.14, OR 0.29, CI 95% 0.06 to 1.50).
*Significance tests for independent factors were based on the loglikelihood ratio test (in bold).
†Significance tests for independent factors with three levels of pairwise comparisons, that is, level 1 vs 2, level 1 vs 3, and level 2 vs 3, were based on the Wald test (in italic).
‡ Raw percentages of patients receiving CA for each level of a factor are presented. Eg, in group 1, for factor Troponin, 222 vignettes are in the category ‘elevated’ and 179 of these received
CA, leading to 179/222×100=80.6%.
CAD, coronary artery disease; LL, lower limit; LRT, loglikelihood ratio test; NA, not applicable; UL, upper limit.
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levels. In patients with severe renal dysfunction, cardiolo-
gists were less likely to perform CA compared to patients
with no or mild to moderate renal dysfunction. For
patients with typical ischaemic changes on the ECG, car-
diologists decided more often to perform CA than for
patients with no changes or for patients with aspeciﬁc
ECG changes. Cardiologists were also more likely to
perform CA for patients with persistent symptoms of
chest pain than for patients without such symptoms.
Presence of risk factors, age and previous CAD was not
signiﬁcantly associated with the decision to perform CA,
with p values ranging between 0.45 and 0.75. The
strengths of the multivariable associations are presented
in terms of ORs and associated 95% CIs. Also in paren-
theses, the ORs and CIs of the univariable analyses are
presented for comparison (table 4).
Information derived from a cardiac risk score was in
the top three factors that inﬂuenced cardiologists’ deci-
sions the most. Although the likelihood ratio test sug-
gested a signiﬁcant effect of the availability of a risk
score on the decision to perform CA (p=0.02), subse-
quent pairwise comparisons between the three levels of
risk score with the Wald test did not provide conclusive
evidence about the nature of this effect. Associated p
values of the Wald test were all above 0.05. Further ana-
lyses revealed that there was a strong association (ie,
partial confounding) between the provision of a risk
score and a patient’s age as presented in the vignette.
Conclusions about the contributions of age and risk
score by inspecting these factors separately could there-
fore not be made. The combined factor for age and risk
score, however, was signiﬁcantly associated with the deci-
sion to perform CA (p=0.003). This despite problems
with convergence of the multivariable model, possibly
related to fairly extreme probabilities connected to age
lower than 70 years and low-risk score, and age higher
than 80 years and high-risk score. In elderly patients
(>80 years) with high-risk scores, cardiologists were more
hesitant in their decision to perform CA than in
younger patients with intermediate risk scores; OR of
0.15 (95% CI 0.05 to 0.46) for 70–80 years versus age
older than 80 and OR of 0.13 (95% CI 0.04 to 0.83) for
the comparison of patients younger than 70 and older
than 80 years. Further, in younger patients (<70 years)
with low risk scores, cardiologists were more likely to
decide on performing CA than in patients aged between
70 and 80 years with intermediate risk scores (OR=4.58,
95% CI 1.88 to 11.14).
Block effects
Although block effects are signiﬁcant (p≤0.05), the per-
centage explained deviance for blocks was relatively
small: 2.1% in group 1 and 3.4% in group 2. For group
2, the analysis without blocks in the model yielded
similar results, except for factor risk score: the percent-
age explained deviance for risk score dropped from
14.3% to 3.8%. Again, we have to concede that conclu-
sions with respect to the impact of risk score alone on
performing CA cannot be drawn with sufﬁcient
conﬁdence.
DISCUSSION
When deciding to perform in-hospital CA (within
72 hours after patient admission) in patients with sus-
pected NST-ACS, cardiologists tend to rely mostly on the
following three sources of clinical information: troponin
levels, ECG changes and renal function. In our binary
choice experiment, cardiologists decided more often to
perform CA in vignettes representing patients with ele-
vated troponin levels and in patients with typical ischae-
mic changes on the ECG. In contrast, in vignettes
representing patients with severe renal dysfunction, car-
diologists seemed to be more hesitant to perform CA.
Persistent symptoms of chest pain, previous CAD and
the presence of risk factors had limited impact on the
decision whether or not to perform CA. Since effects of
risk score were strongly associated (ie, partial confound-
ing) with age, no ﬁrm conclusions could be drawn
about the separate contributions of risk score and age
on cardiologists’ decisions.
With CA, there is a small risk for complications. It is
therefore recommended by the guidelines that physi-
cians take several criteria into account when assessing a
patient and subsequently deciding on a conservative or
invasive approach.1 2 20 21 In the current study, troponin
and ECG changes were considered most important in
decision-making, which is in line with the guideline
recommendations where both factors are deﬁned as
primary features of high risk for adverse cardiac events,
and thus with a clear indication for invasive manage-
ment.1 2 The guidelines consider patients with (severe)
renal dysfunction as high risk for adverse cardiac events
as well, and therefore recommend invasive treatment.
However, the results in our study suggest that cardiolo-
gists were less likely to opt for CA in patients with severe
renal dysfunction compared to patients with mild to
moderate or no renal dysfunction. This treatment risk
paradox, in which patients at low risk for adverse cardiac
events are more likely to receive invasive treatment than
high-risk patients, has been reported before in patients
with NST-ACS with renal dysfunction.22–24 Although
several studies demonstrated that invasive treatment in
patients with severe renal dysfunction was associated
with a reduction in rehospitalisation together with a sig-
niﬁcant reduction or trends of reduced risk for death
and reinfarction,12 25–27 cardiologists seem to be hesitant
to perform CA. A possible explanation may be that car-
diologists are hesitant to perform CA, as severe renal
dysfunction is associated with an increased risk of com-
plications.1 21 Another explanation could relate to the
available scientiﬁc evidence regarding the beneﬁts of
early invasive therapy in patients with NST-ACS with
renal dysfunction. For instance, in an editorial on this
topic, the author points out that there is conﬂicting evi-
dence regarding the beneﬁts of early invasive
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management in this patient group, and that the majority
of studies have observational study designs (instead of
experimental designs) which can encompass an
increased risk of confounding and/or have relatively
small study samples.28
Just as in patients with severe renal dysfunction, a
treatment risk paradox was present in elderly patients at
high risk for adverse cardiac events based on a cardiac
risk score outcome. Cardiologists seemed to be more
hesitant to opt for CA in patients over 80 years with a
high-risk score than in patients at intermediate risk and
of a younger age. As mentioned before, perceived
increased risk for complications of treatment and less
beneﬁt for the older patient and patients with renal dys-
function probably plays a role here. Future research
should focus on why in these speciﬁc patient groups the
guidelines are not adhered to.
It has been suggested before that cardiologists may
not take all predictors of adverse cardiac events into
account when deciding on CA.9 29 30 This was also the
case in our study, where information regarding a
patient’s cardiac history and presence of risk factors
hardly inﬂuenced cardiologists’ decision-making.
Cardiac risk scores incorporate all important clinical
factors, and therefore could be, when actively used in
practice, a solution to the aforementioned treatment-risk
paradox. In the past decade, several prospective studies
demonstrated that risk scores were superior to clinical
assessment by the physician alone.30–32 This emphasises
the importance of multifactorial risk assessment as
recommended by the guidelines. Further prospective
research regarding the impact of these scores on
decision-making and patient outcomes is necessary,
given that in this study we were not able to determine
the exact impact of risk score on decision-making.
Study limitations
Several limitations should be taken into account.
First, although cardiologists were repeatedly contacted,
the response rate was low. It was described in the study
protocol that a response rate of 40%, resulting in 385
cardiologists, would be sufﬁcient to estimate main
effects. This sample rate is, however, not reached.
Nevertheless, despite the wider CIs of ORs, several sig-
niﬁcant associations were found. Therefore, this study
provides further insight into decision processes of cardi-
ologists offering a valuable contribution to the modest
number of studies conducted in the ﬁeld of decision-
making in cardiology so far.
Second, possibly only cardiologists with an afﬁnity for
scientiﬁc research participated (ie, selection bias). The
study sample consisted mainly of cardiologists who were
male, 50 years or older and with more than 10 years of
experience in clinical practice. However, this pattern was
the same for both groups of cardiologists, and thus com-
parable in demographics. Unfortunately, statistics regard-
ing the average age and years in practice of all
cardiologists in the Netherlands were not available,
making an assessment of the generalisability of the study
results difﬁcult.
Third, despite our study design, it remained difﬁcult
to determine individual contributions of age and risk
score as these factors were strongly associated (ie, ham-
pered by confounding).
Fourth, the decisions made on the basis of vignettes
can be different from decisions made in a real-life situ-
ation in clinical practice where the patient can actually
be observed at the coronary care unit. In addition, in
daily practice other factors—not included in this
vignette study—might inﬂuence cardiologists’ decisions.
However, results were generally consistent with ﬁndings
from earlier studies. Further, clinical vignette studies
have been shown to be the most practical, cost-effective
and at the same time thorough and valid approach to
measure the process of decision-making.33 34
Finally, the time frame in which cardiologists were
asked to decide on CA was set on ‘performing CA within
72 hours after patient admission (in-hospital)’. Given the
recommendations in the latest guidelines,2 in which it is
not so much a question ‘if’ CA should be performed but
rather ‘when’, it can be debated that timing of CA is also
of interest to investigate. For instance, by adding more
variation in response categories, for example, immedi-
ately, within 24 hours or within 72 hours. However, the
aim was not to measure whether the ‘correct’ decision
was made, but to gain insight into which factors inﬂuence
decisions the most. Furthermore, the latest guidelines
were published after data collection was ﬁnished and it
can be argued that the 2011 guidelines are still up to
date, as implementation of guidelines in practice takes a
considerable amount of time.
CONCLUSIONS
When deciding to perform in-hospital CA (within
72 hours after patient admission) in patients with sus-
pected NST-ACS, cardiologists tend to rely mostly on the
following three sources of clinical information: troponin
levels, ECG changes and renal function. The importance
of age and risk score in separation was difﬁcult to assess,
due to strong association between these factors.
However, in elderly patients at high risk of adverse
cardiac events according to a risk score, cardiologists
seemed to be more hesitant to perform CA than in
younger patients with intermediate risk scores. This hesi-
tance to perform CA was also seen in patients with
severe renal dysfunction. Future research should focus
on decision-making regarding CA in these patient
groups, and on the impact of age and risk scores on
decision-making.
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